ESMO GYNAECOLOGICAL CANCERS



PLATINUM-RESISTANT OVARIAN CANCER: BIOLOGICAL PATHWAYS, RESISTANCE MECHANISMS AND NOVEL TREATMENT OPTIONS

Chairs

Nicoletta Colombo, Milan, Italy Frederik Marmé, Mannheim, Germany

SATURDAY, 22 JUNE 2024

12:20 - 13:20 CEST, AUDITORIUM

12:20	Welcome and introduction	Frederik Marmé, Mannheim, Germany
12:25	Insights in the biology of ovarian cancer: The neglected pathways	Frederik Marmé, Mannheim, Germany
12:37	A clinical case of a patient with platinum-resistant ovarian cancer: Resistance mechanisms and state-of-the-art treatment options for patients who are not eligible for platinum-based therapies	Nicoletta Colombo Milan, Italy
12:49	The promise of antibody drug conjugates (ADCs) in ovarian cancer: Mechanisms of action and emerging therapeutics	Toon Van Gorp Leuven, Belgium
13:01	A clinical case of a patient on anti-folate receptor ADC: Efficacy and safety data from folate receptor targeting in registrational trials	Kathleen Moore Oklahoma City, OK, USA
13:13	Q&A, discussion and concluding remarks	Nicoletta Colombo Milan, Italy

This educational activity is provided by ESMO and supported by ImmunoGen.

immun•gen